Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index; 21 of the 49 sources its claims cite were checked for support.

Clinical trials of new drugs for Alzheimer disease

Open access
Huang, Li-Kai, Chao, Shu-Ping, Hu, Chaur-Jong·2020·Journal of Biomedical Science

Abstract

Current AD drugs, including cholinesterase inhibitors and memantine, can only inhibit dementia symptoms for a limited period and cannot stop or reverse disease progression.

Overview

CoChat Summary

## TL;DR

This review surveys ongoing and recent clinical trials of Alzheimer disease drugs and argues that the field has shifted away from late-stage anti-amyloid strategies toward earlier intervention and more diverse targets. The authors conclude that effective disease-modifying therapies are still lacking, despite some encouraging signals for a few agents.

## Key findings

  • In 2019, there were nine phase 3 anti-amyloid trials for eight drugs, and the number of anti-amyloid phase 3 trials was lower than in 2017 and 2018.
  • Ongoing anti-amyloid trials had largely moved to prodromal or preclinical AD; no ongoing drug trials enrolled patients with advanced AD.
  • Aducanumab showed dose-dependent amyloid removal and, in the updated EMERGE analysis, 23% less decline in CDR-SB, 27% less decline in ADAS-Cog 13, and 40% less decline in ADCS-ADL-MCI versus placebo at 78 weeks; amyloid plaque burden also decreased at 26 and 78 weeks (P < 0.001).
  • Several programs were unsuccessful or stopped for lack of efficacy or other reasons, including azeliragon, pioglitazone, intepirdine, aripiprazole, nilvadipine, and the CNP520 arm of Generation Study 1, which “showed a worsening of cognitive function.”

## Methods

  • The paper is a narrative review of Alzheimer disease clinical trials, organized by therapeutic target: anti-amyloid, anti-tau, antineuroinflammation, neuroprotection, cognitive enhancers, and BPSD-relieving therapy.
  • The authors state they reviewed the current state of clinical trials at clinicaltrials.gov, along with the underlying mechanisms and reasons prior trials failed.
  • Main analysis is descriptive synthesis of trial status, phases, targets, endpoints, and reported outcomes; no original participant-level statistical analysis is reported.

## Limitations

  • The paper does not describe a systematic search strategy, inclusion/exclusion criteria, or formal risk-of-bias assessment; this is evident from the text.
  • It is a review of trial registrations and reported results, so its conclusions depend on available public reports and may be limited by incomplete disclosure of some trial findings; this is evident from the text.
  • The authors do not report pooled effect estimates or meta-analytic results; instead, the evidence is presented trial by trial.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12929-019-0609-7

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 On the basis of the amyloid hypothesis, the consequent events of pathophysiology and clinical course are amyloid accumulation, neuroinflammation, tau accumulation, brain metabolism dysfunction, brain atrophy, cognitive decline (from mild cognitive impairment to dementia), and dementia symptom development. New drugs should target at least one of these events
Fig. 1 On the basis of the amyloid hypothesis, the consequent events of pathophysiology and clinical course are amyloid accumulation, neuroinflammation, tau accumulation, brain metabolism dysfunction, brain atrophy, cognitive decline (from mild cognitive impairment to dementia), and dementia symptom development. New drugs should target at least one of these eventsCC BY · PubMed Central
Fig. 2 Trend of phase 3 trials, 2017–2019, according to the event-related categories at ClincalTrials.gov. a Number of phase 3 trials. b Percentage of phase 3 trials
Fig. 2 Trend of phase 3 trials, 2017–2019, according to the event-related categories at ClincalTrials.gov. a Number of phase 3 trials. b Percentage of phase 3 trialsCC BY · PubMed Central
Fig. 3 Trends of phase 1 and phase 2 trials, 2017–2019, according to the event-related categories in ClincalTrials.gov. The percentages of phase 1 and phase 2 trials
Fig. 3 Trends of phase 1 and phase 2 trials, 2017–2019, according to the event-related categories in ClincalTrials.gov. The percentages of phase 1 and phase 2 trialsCC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 5 Not valid · 18 Not checked · 32 Own results and interpretations

37 more claims · 7 with their cited sources checked

Create a free account to see all 71 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 17
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 84 references

Cited by

See all 702

Metadata

Authors
Huang, L.-K., Chao, S.-P., & Hu, C.-J.
Affiliations
  • National Health Research Institutes (TW)
  • Taipei Medical University-Shuang Ho Hospital (TW)
Corresponding author
Hu, Chaur-Jong
Venue
Journal of Biomedical Science
Published
2020-01-06
Volume
27
Issue
1
Pages
18-18
ISSN
  • 1021-7770 (ISSN-L)
  • 1423-0127
OpenAlex
W3000635098
Cited by
702
References
84
Citations by year
2026: 32 · 2025: 66 · 2024: 94 · 2023: 142 · 2022: 137 · 2021: 146 · 2020: 66
FWCI
73.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biomedical Science (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
Alzheimer's disease, clinical trials, amyloid hypothesis, amyloid-beta, anti-amyloid therapy, anti-tau therapy, cholinesterase inhibitors, NMDA receptor antagonists
MeSH terms
Alzheimer Disease, Cholinesterase Inhibitors, Clinical Trials as Topic, Humans, Receptors, N-Methyl-D-Aspartate, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trials of new drugs for Alzheimer disease. https://app.cochat.ai/papers/10.1186/s12929-019-0609-7
The paper
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science. https://doi.org/10.1186/s12929-019-0609-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.